Welcome to our dedicated page for Actinium Pharmac SEC filings (Ticker: ATNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These include annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K, proxy statements on Schedule 14A and other required submissions that describe the company’s business, risks, governance and financial reporting framework.
For a development‑stage biopharmaceutical company focused on Actinium‑225 targeted radiotherapies, filings can be a key source of detail beyond press releases. In its Form 10‑Q and related disclosures, Actinium discusses the prioritization of ATNM‑400 as its lead program, outlines preclinical data in prostate cancer, non‑small cell lung cancer and breast cancer, and comments on market dynamics around PSMA‑targeted radiotherapies and ARPI therapies. Current reports on Form 8‑K, such as the filing dated November 26, 2025, document material events including annual meeting results, director elections and advisory votes on executive compensation.
Definitive proxy statements (DEF 14A) provide information on the company’s board structure, proposals submitted to stockholders, and matters such as auditor ratification and say‑on‑pay votes. Together, these filings help investors understand Actinium’s governance, capital structure and strategic priorities as it advances programs like ATNM‑400, Actimab‑A, Iomab‑ACT and Iomab‑B.
On Stock Titan, SEC documents for ATNM are paired with AI‑generated highlights that summarize key points from lengthy forms, helping readers quickly identify sections related to targeted radiotherapy development, risk factors, shareholder votes and other topics of interest. Real‑time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and proxy filings, as well as any insider transaction reports on Forms 3, 4 or 5 if filed, are reflected promptly for deeper analysis.
Actinium Pharmaceuticals, Inc. reported the final results of its 2025 annual meeting of stockholders. Stockholders re-elected Class III directors Ajit S. Shetty and June S. Almenoff to serve until the 2028 annual meeting. Mr. Shetty received 5,032,369 votes for and 1,234,852 withheld, while Dr. Almenoff received 5,284,503 votes for and 982,719 withheld, with 9,354,877 broker non-votes for each.
A total of 15,494,573 shares were present in person or by proxy out of 31,195,891 shares of common stock outstanding as of the October 15, 2025 record date. Stockholders approved all proposals, including, on a non-binding basis, the compensation of named executive officers (4,481,875 for, 1,541,460 against, 243,885 abstain, and 9,354,877 broker non-votes) and three years as the frequency for future advisory votes on executive pay.
Actinium Pharmaceuticals (ATNM) filed its Q3 2025 10‑Q, reporting a net loss of $5.1 million and cash and cash equivalents of $53.4 million as of September 30, 2025. Total revenue was $0.09 million from grant income. Operating expenses fell to $5.8 million from $12.6 million a year ago, driven by lower R&D and G&A.
For the nine months, net loss was $27.9 million; operating cash use was $19.3 million. The company recorded $8.8 million of stock‑based compensation expense tied to option cancellations in 2025. Long‑term license revenue deferred of $35 million remains tied to potential EU regulatory outcomes for Iomab‑B. Shares outstanding were 31,195,891 as of November 14, 2025.
Pipeline updates highlight preclinical data for ATNM‑400 across NSCLC, prostate, and breast cancer, with additional breast cancer data slated for December 11, 2025. Under its NCI CRADA, Actimab‑A trials are advancing, with initial proof‑of‑concept readouts for Iomab‑ACT SCD and a CAR‑T setting expected in the first half of 2026.
Actinium Pharmaceuticals (ATNM) scheduled its 2025 Annual Meeting for 9:30 a.m. ET on November 26, 2025 at The Garden City Hotel in Garden City, NY. Stockholders are asked to vote on four items.
Proposal 1 seeks to elect Ajit Shetty and June S. Almenoff as Class III directors for three-year terms. Proposal 2 asks to ratify CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Proposal 3 requests a non-binding advisory vote on named executive officer compensation. Proposal 4 requests a non-binding advisory vote on how often to hold future say‑on‑pay votes.
The Board unanimously recommends voting FOR Proposals 1, 2, and 3, and “EVERY THREE YEARS” for Proposal 4. Voting is available by Internet, telephone, mail, or in person with advance registration. A quorum requires at least 34% of voting power present in person or by proxy.
Actinium Pharmaceuticals insider filing: Sandesh Seth, the company's Chief Executive Officer and a Director, reported a transaction dated 08/18/2025 relating to his common stock holdings in Actinium Pharmaceuticals (ATNM). The Form 4 discloses that 120,900 shares were withheld at a price of $1.71 to satisfy tax withholding obligations arising from the vesting of 300,000 restricted stock units (RSUs) that were granted to Mr. Seth on 08/17/2022. After the withholding, Mr. Seth beneficially owned 184,481 shares. The filing explains the RSUs were granted in exchange for previously issued warrants that had vested earlier and whose expiration dates and exercise were adjusted by the board to align his interests with stockholders.
Actinium Pharmaceuticals (ATNM) reported no revenue for the quarter and six months and recorded a net loss of $6.9 million for the three months and $22.8 million year-to-date, or $0.73 per share for six months on 31.2 million shares outstanding. Cash and cash equivalents totaled $59.9 million (plus $0.3 million restricted cash) versus $72.9 million at year-end, and stockholders’ equity declined to $19.0 million from $32.8 million.
The company recorded $8.8 million of stock-based compensation in the six-month period related to the cancellation of options, and operating expenses were $24.1 million for six months, driven by R&D and G&A. License consideration of $35.0 million received under its Immedica agreement remains recorded as long-term deferred revenue until EU regulatory milestones are satisfied. Material legal actions include a securities class action and consolidated derivative complaints; lead plaintiffs were recently appointed.
The Vanguard Group has filed Amendment No. 1 to Schedule 13G for Actinium Pharmaceuticals (ATNM), triggered by the 30 June 2025 reportable event. The filing discloses 1,371,840 ATNM common shares beneficially owned, equal to 4.39 % of the outstanding class, placing Vanguard below the 5 % threshold noted in Item 5.
According to Item 4, Vanguard holds no voting power—sole or shared—but retains dispositive authority over nearly all of the shares (sole: 1,362,947; shared: 8,893). Vanguard is filing in its capacity as an investment adviser (Rule 13d-1(b)(1)(ii)(E)); the ownership is on behalf of its advisory clients, none of which individually own more than 5 %. Certification in Item 10 confirms the stake is held in the ordinary course of business and not for the purpose of influencing control of ATNM.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
